A single injection of a new gene therapy treatment from Avalanche Biotech could possibly stop the advance of neovascularization in the wet form of AMD for several years. Human clinical trials are currently underway.

Here is how I commented about this breakthrough in my writeup:

“If this approach is successful, it could result in a “game change” in the way wet AMD is treated. Instead of multiple injections to gain control of neovascularization, one injection at the first signs of neovascularization could stop it dead in its tracks and the effect could last, potentially, for several years.

In addition, it is conceivable that patients at risk of developing wet AMD could receive a therapeutic injection of AVA-101 to prevent the occurrence of wet AMD. This would be a definite paradigm shift in the treatment of AMD.

With the human clinical testing now underway, we should have an indication of initial results with this unique approach within about a year.

Stay tuned!”

In a nutshell, Avalanche has developed a proprietary drug delivery system, known as Ocular BioFactoryTM, that continuously secretes a therapeutic protein over an extended period following a single subretinal injection, thus avoiding the need for frequent intraocular injections of recombinant anti-VEGF protein.

To read more about this potential “game changing” breakthrough in the future treatment of wet AMD, please follow this link ^[1].